Pharmaceutical Market Europe • April 2022 • 38-40
APPOINTMENTS
Roche
William Pao
Pfizer has appointed Dr William Pao as its new executive vice president and chief development officer. Pao succeeds Rod MacKenzie, following MacKenzie’s announcement of his retirement after a 35-year career at Pfizer. Pao will also serve as a member of Pfizer’s Executive Leadership Team. Pao previously worked at Roche as the company’s head of pharma research and early development (pRED), overseeing the discovery and early development of new molecular entities to help in the treatment of diseases relating to cancer, ophthalmology, neuroscience, rare and infectious diseases, immunology and rare blood disorders across seven sites worldwide. Alongside his role at Roche, Pao served as a member of the company’s Enlarged Corporate Executive Committee.
Ipsen
Guy Oliver
Ipsen has appointed Guy Oliver as general manager of its UK and Ireland affiliate. Oliver will also act as head of site for Ipsen’s Global Hub in Slough and will lead Ipsen’s growing commercial presence in the UK & Ireland. With an extensive background in oncology, neurosciences and rare diseases, Oliver joins from his former role as general manager for Belgium and Luxembourg at Novartis.
Merck
Julie Gerberding
Merck and Co has announced that Julie Gerberding, chief patient officer and executive vice president of population health and sustainability, will be retiring in May 2022. Gerberding leaves after 12 years with the company and was instrumental in the company’s social, environmental and governance strategy. Gerberding will become CEO of the Foundation for the National Institutes of Health on 16 May.
Takeda
Rajeev Venkayya
Rajeev Venkayya has stepped down as president of Takeda’s global vaccine business unit, a role he had held since 2014. His work involved overseeing a pipeline for advanced vaccine research for norovirus and dengue. Previously Venkayya worked at the Bill & Melinda Gates Foundation as director of vaccine delivery and also served at the White House as special assistant to the US president.
Cline Scientific
Hanne Evenbratt
Cline Scientific has appointed Hanne Evenbratt as its new vice president of research & development. Evenbratt will lead the research, product development and production efforts. This includes directing Cline’s preclinical projects (StemCART and CellRACE) into the next phases. Evenbratt previously served as Cline Scientific’s director of product development and has been with the company since 2014.
Neuraxpharm Group
Tom Coogan
Neuraxpharm Group has appointed Tom Coogan as country manager for Ireland. He will focus on establishing Neuraxpharm as a CNS specialist. Coogan has over 30 years’ experience in pharmaceuticals, alongside successfully building the Ireland business of Grünenthal Pharma as a leading player in the field of pain management and related diseases in Ireland.
Cline Scientific
Lars Peterson
Cline Scientific has appointed Lars Peterson as a new advisor for StemCART, Cline’s cell-based cartilage repair product. A Professor Emeritus and orthopaedic surgeon, Peterson works in orthopaedics and sports medicine. For 38 years, Lars Peterson has been a member of the Sports Medical Committee of FIFA and is a founding member of F-MARC (FIFA Medical Assessment and Research Centre).
RevoluGen
Nick McCooke
RevoluGen has appointed Nick McCooke as its strategic advisor. McCooke was founding CEO of Solexa, CEO of Longas Technologies and chief business officer of DNA Electronics. He has served in non-executive roles at Evonetix, Bioventix and Biogazelle and executive positions at Oxford Cancer Biomarkers, Pronota, Rapigene, Innovex, Quintiles and Celltech.
Macomics
Mario Leonardo Squadrito
Macomics has appointed Mario Leonardo Squadrito to its advisory panel. Squadrito is project leader in the Unit of Targeted Cancer Gene Therapy at the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy. Squadrito’s research is focused on developing new gene-based strategies to convey antitumour molecules to liver metastases to activate immune functions.
Roche
Johannes Clevers
Roche has appointed Johannes Clevers as the company’s new head of Roche pharma research and early development (pRED). He succeeds William Pao, who had held this position since 2018. Clevers will be stepping down from his position on its Board of Directors, a role he has held since 2019. He will be based in Basel and will become a member of the enlarged Corporate Executive Committee. Clevers holds the positions of Professor of molecular genetics at University of Utrecht, principal investigator at Hubrecht Institute, alongside his work at the Princess Máxima Center for paediatric oncology. He also serves on various scientific boards, including the Francis Crick Institute, and is a member of The Royal Society in the UK.
F-star Therapeutics
James Sandy
F-star Therapeutics has appointed James Sandy as its chief development officer. Sandy will lead the clinical development and advancement of F-star’s pipeline. With over 35 years’ experience in the biotech and pharmaceutical industries across all phases of drug development, Sandy has worked in senior positions at Pfizer and served as chief development officer at Ellipses Pharma, Immunocore and Creabilis Pharmaceuticals.
Sanofi
Carole Ferrand
Sanofi has appointed Carole Ferrand as an independent director. Ferrand serves as chief financial officer of the Capgemini Group and as director of Fnac Darty. Ferrand has a strong background in leadership, having worked at Sony France for ten years as its chief financial officer. In 2013, Ferrand was finance director of the Artémis Group and served on the Board of Directors of Capgemini for two years.
Sanofi
Emile Voest
Sanofi has appointed Emile Voest as an independent director. Voest is currently director of Cancer Core Europe and has worked as a Professor of medical oncology at the University of Utrecht, leading his research group at the NKI and Oncode Institute. He is co-founder and non-executive board member of the Hartwig Medical Foundation and is a board member of the Center for Personalized Cancer Treatment.
Sanofi
Antoine Yver
Sanofi has appointed Antoine Yver as an independent director. In 2021, Yver served as chief medical officer of Centessa Pharmaceuticals. Previously, he held senior roles at the Aventis Group as senior director, oncology global clinical development, and led global oncology development at AstraZeneca. Yver also served as executive vice president, global head of oncology research and development at Daiichi Sankyo.
Verona Pharma
James Brady
Verona Pharma has appointed James Brady as a non-executive director to its Board. He has an extensive background of over 30 years in biopharmaceutical leadership at AstraZeneca in the US, Europe and China. Recently, Brady has served as chief financial officer of MedImmune – the biologics discovery and development division of AstraZeneca.
insitro
Jevan Soo Lenox
insitro has appointed Jevan Soo Lenox as chief people officer. Lenox brings to his position over 15 years of industry experience, having built transformative and expansive global companies across an array of workplaces. Lenox previously worked as the chief of people and culture officer for Stitch Fix, held business leadership roles at Square and was chief people officer at Blue Bottle Coffee.
insitro
Martha Rook
insitro has appointed Martha Rook as chief technical operations officer. Rook joins with over 20 years of industry experience in molecular biology, diagnostics development and gene therapy manufacturing. Rook worked at Sigilon Therapeutics as its chief technical operations officer, responsible for analytics, manufacturing and supply chain organisations. Rook also worked at MilliporeSigma.
Ixaka
Nick Robbins-Cherry
Ixaka has appointed Nick Robbins-Cherry as its new chief financial officer. He joins the company with 30 years of experience as a chartered accountant. His work has involved fundraising, public markets and private equity and he has also served in financial and commercial roles in pharmaceuticals, software and telecoms businesses. He was previously also CFO at Vorboss.
Lucid Group
Paul Cutler
Lucid Group has appointed Paul Cutler as its chief people officer. Cutler brings over 20 years’ experience to the position, spanning both commercial and human resources roles over his career. Cutler previously served as managing director at Mandala UK and prior to that, worked as Travelex’s chief people officer. Cutler will help to build learning agendas and oversee HR objectives.
OPEN Health
David Thompson
OPEN Health has appointed David Thompson as chief executive officer for evidence and access. Thompson is a health economist with over 25 years’ experience in conducting real-world research and HEOR consulting for clients in the biopharmaceutical sector. He served as editor-in-chief of the ISPOR publication Value & Outcomes Spotlight from 2008 to 2020 and is a current member of the ISPOR Board of Directors.
Resonant Group
Mark Corbett
Resonant Group has appointed Mark Corbett as its chief innovation officer. Corbett will be accountable for operating innovation across the company and driving the growth of its patient experience and insights business, Origins Insights. Corbett brings nearly 30 years of industry experience, having worked as a director at MEMCOR, as an executive VP at Inceptua Group and as MD at Clinigen Group.
Nucleus Global
Trevor Telo
Nucleus Global has appointed Trevor Telo as its creative director. Telo has over 20 years' experience in medical communications having worked in creative agencies on both healthcare and consumer brands, using traditional and creative advertising and marketing. Telo has worked as a senior art director at Fishawack Health, as creative director at Havas Life Medicom, and held roles at Langland and Wunderman.
Hanover Health
Malcom Qualie
Hanover Health has appointed Malcom Qualie as its new senior advisor, focused on market access. From 2013 to 2022, Qualie was medicines lead for specialised commissioning at NHS England. In his new role, Qualie will use his expertise in client engagement to support clients in understanding the NHS environment as the health system seeks to agree more deals with companies on innovative therapies.
OVID Health
Cameron Miller
OVID Health has appointed Cameron Miller as an associate director. Miller will be integral in advising the agency’s growing patient advocacy affairs client roster. Before joining OVID, Miller led Sanofi UK’s public affairs and advocacy work in rare diseases and vaccines. Miller was The Brain Tumour Charity’s Head of Policy and Public Affairs where he secured Ministerial commitment to improve outcomes for brain tumour patients.
AXON
Godfrey Lisk
AXON has appointed Godfrey Lisk as a director, adding his strategic partnership and collaborative skills to the company’s leadership team. With over 11 years’ experience in medical communications, Lisk was the scientific services director at Chameleon, gaining extensive experience in developing medical and scientific talent. Previously, Lisk was a research fellow at the National Institutes of Health (NIH) in the US for eight years.
imc group
Sue Couldery
imc group has appointed Sue Couldery as its chief financial officer from Teneo – an international comms and advisory firm – where she was CFO for EMEA, where she oversaw 750 employees. Couldery brings extensive financial management expertise to the position, having worked as the finance director at GPC International and Interbrand. Couldery also served as a non-executive Chairman at Yonder Consulting.
Dice Medical Communications
Colin Wheeler
Dice Medical Communications has appointed Colin Wheeler as its new medical director. Joining on a part-time basis, Wheeler brings 23 years’ experience in the pharmaceutical industry and as a medical practitioner, working in the NHS in oncology and haematology. Previously, Wheeler has worked as a medical advisor in research and development, eventually setting up his own pharmaceutical business.
Onyx Health
Alison Davies
Onyx Health has appointed Alison Davies as an associate director. Davies has a background of over 30 years’ experience in the delivery and support IT, not-for-profit, heritage sector, healthcare events and medical communications. She served as an associate director of scientific communications for Weber Shandwick and BSMG Worldwide. Davies also serves on various international advisory boards.
Onyx Health
Sarah Walton
Onyx Health has appointed Sarah Walton as its new account director. Walton is an experienced PR and events director with a background of working in marketing communications and employer brand industries. Walton worked at Dawson Walker Communications for over 20 years and previously helped to deliver programmes for Shell, as well as campaigns for Philip Morris International.
Onyx Health
Lynsey Carr
Onyx Health has appointed Lynsey Carr as its senior designer. Carr brings over two decades of experience to the company, having delivered creative and targeted projects including multinational software companies, pharmaceutical companies and established creative agencies. Carr worked on various national newspaper titles including The Daily Express, The Daily Mirror and The Scotsman.